ST. LOUIS, Oct. 29, 2015 /PRNewswire/ -- Sigma-Aldrich
Corporation (NASDAQ: SIAL), a leading Life Science and Technology
company, today announced that it has signed an agreement to acquire
the Duolink® product portfolio from Olink Bioscience.
The acquisition includes intellectual property, sales, marketing
and manufacturing assets.
The newly acquired product line is designed for researchers
studying biological pathways and seeking improved sensitivity to
uncover disease biomarkers. Since 2013, Sigma-Aldrich has
distributed Duolink reagents, along with pre-validated antibody
pairs for proximity ligation assays (in situ PLA®).
"We are excited about the acquisition of the Duolink product
portfolio. Duolink is valuable to our customers and complements the
rest of Sigma-Aldrich's Protein Biology portfolio," said
Amanda Halford, Vice President,
Academic Research at Sigma-Aldrich. "Owning the Duolink
technology will provide Sigma-Aldrich with opportunities to develop
new products, as well as advance our existing technologies."
Duolink Technology, based on PLA technology, enables researchers
to visualize low levels of proteins, protein modifications and
individual protein interactions directly in fixed cells and tissue
samples without the need for overexpression. This technology can
significantly enhance the rigor and reproducibility of scientific
experiments, aided by dual recognition of antibody pairs.
"Duolink has been a very important product in the history and
development of Olink, and we feel that with this acquisition by
Sigma-Aldrich, it will be in very good hands and continue to be a
great success," said Jon Heimer, CEO
of Olink Bioscience. "We will now focus our resources on further
developing our Proseek® Multiplex product line for
human protein biomarker research, as well as expanding our global
presence by establishing local commercial organizations in
Europe and North America, and continuing to develop new
innovative tools for the scientific community."
"Duolink technology is transforming the way scientists study
biological pathways. It allows interactions between proteins at the
endogenous levels to now be visualized, providing researchers with
reproducible data they can see," said Halford. "The acquisition of
Duolink allows Sigma-Aldrich to provide comprehensive solutions for
enabling experimental reproducibility, with continued reliability
in supply and quality."
Cautionary Statement: The foregoing release contains
forward-looking statements that can be identified by terminology
such as "will provide," "will advance," "will allow" or similar
expressions, or by expressed or implied discussions regarding
potential future revenues from products derived there from. You
should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management
regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. There can be
no guarantee that this or any other product offering will assist
the Company to achieve any particular levels of revenue in the
future. In particular, management's expectations regarding this
product offering could be affected by, among other things, the
Company's ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general;
government, industry and general public pricing pressures; the
impact that the foregoing factors could have on the values
attributed to the Company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About Sigma-Aldrich: Sigma-Aldrich, a
leading Life Science and Technology company focused on enhancing
human health and safety, manufactures and distributes 250,000
chemicals, biochemicals and other essential products to more than
1.4 million customers globally in research and applied labs as well
as in industrial and commercial markets. With three distinct
business units - Research, Applied and SAFC Commercial -
Sigma-Aldrich is committed to enabling science to improve the
quality of life. The Company operates in 37 countries, has
approximately 9,700 employees worldwide and had sales of
$2.79 billion in 2014. For more
information about Sigma-Aldrich, please visit its website at
www.sigma-aldrich.com.
Sigma-Aldrich and Sigma are
trademarks of Sigma-Aldrich Co, LLC registered in the US and other
countries.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sigma-aldrich-acquires-duolink-product-portfolio-from-olink-bioscience-300168400.html
SOURCE Sigma-Aldrich